pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Pulmonology · news · pharmadog
← back to Pulmonology
News · Pulmonology
723
stories
15d
6 potential blockbusters that could pave China’s path to 2030 ambitions
biospace
15d
Neurocrine defends Prader-Willi drug after another patient death
biospace
15d
UniQure gets an FDA decision date; Teva scraps brain drug study
biopharma dive
15d
AbbVie abandons phase 2 solid tumor drug over ‘limited benefit’
fiercebiotech
15d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
16d
Philips sets aside $322M for proposed DOJ settlement over sleep apnea device recall
fiercebiotech
16d
Early Alert: Compact Medical Removes and Updates Use Instructions for ButterflyBVM Bag-Valve-Mask Resuscitators
fda medwatch
16d
Washington state resident dies from bird flu following exposure to infected cattle
stat
16d
Significant stock movers of October: Biohaven climbs, ArriVent dives
biospace
16d
CinRx teams with Sam Waksal's Graviton on ROCK2 for PAH, other cardio conditions
endpoints
16d
OpenAI-funded Biossil snags Theriva's unwanted antibiotic degrader portfolio for up to $91M
fiercebiotech
16d
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
stat
16d
Drugmakers rush to pair up with Summit’s ivonescimab ahead of key verdict
biospace
17d
BridgeBio gears up for rare muscular dystrophy launch with FDA approval in sight
biospace
19d
FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis
fda press
19d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
19d
Assessing Merck and Moderna’s mRNA cancer vaccine
stat
19d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
19d
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
biospace
19d
With Setara, the team behind Actio opens its second act
biopharma dive
19d
Opinion: What a mother’s 1834 letter about measles tells us about MAHA
stat
20d
Bambusa shoots past IPO targets as Aspen trims offering
fiercebiotech
20d
Roche launches differential diagnosis test for mesothelioma
fiercebiotech
20d
Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
fiercebiotech
20d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
20d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
20d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
20d
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
biospace
20d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
21d
Early Alert: Medline Removes or Corrects All Medline Brand Beds and Accessories
fda medwatch
← prev
page 3 of 25
next →